#United States #Nashville #Karen Lynch #Optura #Bruce Broussard

Optura Welcomes Esteemed Advisors to Propel Healthcare AI

In a significant move to amplify its mission, Optura, a pioneering enterprise healthcare platform focused on delivering ROAI™ (Return on AI Investment), has welcomed Bruce Broussard and Karen Lynch as strategic advisors. Both Broussard, the former President and CEO of Humana, and Lynch, the former President and CEO of CVS Health, bring extensive expertise from high-level positions in the healthcare industry, making their involvement pivotal as Optura seeks to address a critical gap in AI performance measurement in healthcare.

The Challenge of AI in Healthcare

As healthcare organizations increasingly commit to enterprise AI, many still struggle to provide concrete answers to questions about the effectiveness of these initiatives. According to McKinsey's 2025 State of AI survey, only 39% of organizations report a significant impact on their bottom line from AI, despite its widespread adoption. An MIT analysis of over 300 enterprise deployments revealed that 95% of generative AI pilots achieve no measurable business impact, compounding the worry that the billions spent on AI each year may not yield the expected returns.

This disconnect shows that AI is not just a planning issue; it has transitioned into a performance problem, highlighting the need for robust frameworks that can link investment to tangible results. Optura's mission is precisely to bridge this accountability gap.

Visionary Leadership

Broussard, who played a crucial role in growing Humana’s revenue from $39 billion to nearly $93 billion in over a decade, highlights the innovations in healthcare investments but emphasizes the challenge in measuring true value creation. He states, “ROAI provides a much-needed framework for connecting investment to impact, and Optura is building it the right way.” His words reflect a pressing concern within the industry: demonstrating the real impact of financial investments in AI.

Lynch echoes this sentiment, having led CVS Health to become one of the most consumer-oriented health enterprises in the nation. She stresses the importance of actual performance over mere promises, stating, “The promise of AI in healthcare was always about doing more for people — better care, better access, better outcomes. But promise without performance is just noise.” Her commitment to leveraging AI for meaningful productivity aligns seamlessly with Optura's goals.

A Coalition of Expertise

Broussard and Lynch join a group of seasoned advisors from respected organizations such as Humana, Optum, UnitedHealth Group, and the Boston Consulting Group. Together, they possess a collective knowledge that surpasses a century of healthcare leadership. These advisors have not only managed large healthcare organizations but have also been directly involved in operational and technological roles that drive AI from concept to execution.

Andy Fanning, Co-Founder and CEO of Optura, states, “The advisors who've aligned with Optura have run the largest healthcare organizations in the country, where the stakes of getting AI wrong aren’t measured in a wasted budget. They're measured in people’s health.” This statement underlines the responsibility that comes with healthcare investments.

More Than Numbers

Optura is poised to redefine how healthcare leaders view and interact with AI investments. It aims to transform corporate priorities into operational AI agents, facilitating improved decision-making. The platform allows organizations to simulate potential returns before committing financial resources, providing an essential tool for tracking performance against projections on a unified intelligence layer.

With more than $2 billion in healthcare AI initiatives currently running on Optura and a tracked value of $120 million based on a staggering 700% ROAI on in-flight initiatives, the platform is already making its mark. Over 250 new use cases have been identified, solidifying Optura's role as a trusted partner for leading enterprise health plans and provider organizations.

In conclusion, as the healthcare sector navigates the complexities of AI investments, the addition of industry leaders like Bruce Broussard and Karen Lynch to Optura’s advisory team provides a promising beacon of hope for measuring and enhancing the impact of AI in healthcare. Their combined experience and recognition of the importance of ROAI signal that the industry is moving towards a future where AI is aligned closely with operational success and improved patient outcomes.